Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | DRD3 | P35462 | 4/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31540886 | 0.91 | PRKCI (0.47) | PRKCIDYRK1ADRD2DRD3DYRK2 | |
| SCHEMBL31540883 | 0.91 | PRKCI (0.47) | PRKCIDYRK1ADRD2DRD3DYRK2 | |
| SCHEMBL7082445 | 0.87 | DRD2 (0.45) | PRKCIDYRK1ADRD2DRD3DYRK2 | |
| SCHEMBL15290407 | 0.87 | DRD2 (0.45) | PRKCIDYRK1ADRD2DRD3DYRK2 | |
| SCHEMBL10487287 | 0.85 | DRD2 (0.44) | PRKCIDYRK1ADRD2DRD3DYRK2 | |
| SCHEMBL12438576 | 0.82 | DYRK1A (0.46) | PRKCIDYRK1ADRD2DRD3DYRK2 | |
| SCHEMBL1701459 | 0.82 | AHR (0.42) | PRKCIDYRK1ADRD2DRD3DYRK2 | |
| SCHEMBL13100028 | 0.82 | PKLR (0.43) | PRKCIDYRK1ADRD2DRD3DYRK2 | |
| SCHEMBL9377723 | 0.80 | PRKCI (0.37) | PRKCIDYRK1ADRD2DRD3DYRK2 | |
| SCHEMBL2131895 | 0.78 | PRKCI (0.36) | PRKCIDYRK1ADRD2DRD3DYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115651448-A | Conductive ink with n-type conductivity and preparation and application thereof | 华南理工大学 | 2023-01-31 | — | — | CN | claimed |
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NodThera Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| CN-119230299-A | Solid-state capacitor and preparation method thereof | 聚镕光电(广州)新材料科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119108509-A | Negative electrode plate, preparation method thereof and secondary battery | 蜂巢能源科技股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-11840543-B2 | Compounds and uses | THE UNIVERSITY OF QUEENSLAND (AU) | 2023-12-12 | — | — | US | disclosed |
| US-11840543-B2 | Compounds and uses | THE UNIVERSITY OF QUEENSLAND (AU) | 2023-12-12 | — | — | US | disclosed |
| US-11829036-B2 | Optically anisotropic multilayer product and method for producing same | ZEON CORPORATION (JP) | 2023-11-28 | — | — | US | disclosed |
| US-20100266507-A1 | LUMINESCENT COMPOUNDS | SETA BIOMEDICALS, LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100266507-A1 | LUMINESCENT COMPOUNDS | SETA BIOMEDICALS, LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | disclosed |
| US-7208512-B2 | Benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2007-04-24 | — | — | US | disclosed |
| US-7208512-B2 | Benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2007-04-24 | — | — | US | disclosed |
| US-7208512-B2 | Benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2007-04-24 | — | — | US | disclosed |
| US-20060009503-A1 | Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma | NOVARTIS AG (CH) | 2006-01-12 | — | — | US | disclosed |
| EP-1455780-A4 | NOVEL BENZODIFURANIMIDAZOLINE AND BENZOFURANIMIDAZOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON INC (CH) | 2005-04-06 | — | — | EP | disclosed |
| EP-1455780-A1 | NOVEL BENZODIFURANIMIDAZOLINE AND BENZOFURANIMIDAZOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | Alcon, Inc. (CH) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003053436-A1 | NOVEL BENZODIFURANIMIDAZOLINE AND BENZOFURANIMIDAZOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NLRP3, NOD1, NLRP1 | PRKCI 2063/4885DYRK1A 4802/4885DRD2 4867/4885 |
| US-20100266507-A1 | LUMINESCENT COMPOUNDS | SQLE, COASY, ZKSCAN2 | PRKCI 407/4885DYRK1A 2372/4885DRD2 4400/4885 |
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | PRKCI 2063/4885DYRK1A 4802/4885DRD2 4867/4885 |
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | PRKCI 2390/4885DYRK1A 4428/4885DRD2 4758/4885 |
| US-20060009503-A1 | Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma | AIFM1, MFN2, SIRT1 | PRKCI 2909/4885DYRK1A 3558/4885DRD2 2460/4885 |
| US-11840543-B2 | Compounds and uses | NLRP3, NOD1, IAPP | PRKCI 1575/4885DYRK1A 2843/4885DRD2 3770/4885 |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | PRKCI 4070/4885DYRK1A 3821/4885DRD2 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.